-
ACTG ANNOUNCES LAUNCH OF ITS FIRST HIV CURE CLINICAL TRIAL IN AFRICA
Jul 16, 2024
-
Study will enroll participants who initiated treatment shortly after acquiring HIV
Apr 22, 2024
-
A5341s: A5321 Sampling Substudy Longitudinal Sampling Substudy of A5321 is collecting information from measures of different HIV reservoirs, including…
Open and enrolling
HIV Cure
-
Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas…
Closed to accrual
HIV Cure
The duration of the study is up to 72 weeks (a year and a half).
-
AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV-infected cells that…
Open and enrolling
HIV Cure, Treatment Experienced
Participants will be expected to stay in the study for about 7 years.
-
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Closed to accrual
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure…
Closed to accrual
HIV Cure
Up to 9 weeks per participant after a screening period of up to 90 days.
-
Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment…
Open and enrolling
HIV Cure
Maximum of 2 years. Arm A will receive one dose of N-803 at Week 1 and then every 3 weeks for a total of eight doses.
